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shown to affect biomaterial degradation in vivo , which cannot be precisely simulated in vitro. [ 6 ] Attempts to quantify polymeric scaffold degradation in vivo have been inconsistent due to the diffi culty of separating the infi ltrated/regenerated tissues from the porous scaffolds. [ 6 ] An in situ real-time method to accurately monitor and quantify scaffold degradation and tissue regeneration processes without traumatically explanting samples or sacrifi cing animals is urgently needed. [ 2, 7 ] To achieve this goal, it is essential that the biodegradable polymers can be used as non-invasive bioimaging probes, in addition to providing a suitable cell growth substrate. Recently, fl uorescent dye conjugated polyethylene glycol (PEG)/dextran hydrogels were developed to track the in vivo material degradation. [ 7 ] However, such a model system may bring about concerns of photobleaching and cytotoxicity that are often associated with the use of traditional organic dyes. The loss of the conjugated fl uorescent dyes on the polymers may complicate the understanding on fl uorescence loss and material degradation.
Biodegradable polymers, mostly polylactones, have also been widely used as theranostic nanomedicine platforms for targeted drug delivery and high-throughput imaging. [ 8 ] Generally, imaging agents alone cannot be used as drug delivery carriers and vice versa. Therefore, the conjugation/encapsulation of imaging agents onto/into drug delivery carriers is normally required to generate theranostic nanobiomaterials. Polymeric nanoparticles are usually conjugated with additional organic dyes or quantum dots (QDs) for fl uorescence imaging. [ 9 ] However, the poor photobleaching-resistance and low dye-to-particle conjugation ratios of organic dyes as well as the toxicity and poor hydrodynamic stability of QDs prevent their practical uses in vivo. [ 10 ] Encapsulating/conjugating imaging agents in/ on nanoparticles may result in increased particle sizes, added complexity, and higher risk of adverse biological reactions. [ 11 ] Moreover, targeting ligands have to share conjugation sites with imaging agents, which may result in insuffi cient conjugation, thus reducing both the targeting and imaging effi ciency. [ 12 ] Such challenges might be resolved by using biodegradable fl uorescent polymers that exhibit dual-functionality as drug delivery carriers and imaging probes.
To address the aforementioned concerns, we create a method to develop biodegradable imaging-detectable polymers, biodegradable photoluminescent polylactones (BPLPLs), via a ring-opening polymerization of lactones initiated by our recently developed biodegradable photoluminescent polymers (BPLPs). [ 13, 14 ] BPLPs are fully degradable pre-polymers that are synthesized by a polycondensation reaction of biocompatible monomers such as citric acid, α-amino acids, and diols. [ 13 ] BPLPs display high quantum yields (up to 79%), The use of biodegradable polymers, in particular hydrolytically degradable polylactones such as polylactide (PLA), polyglycolide (PGA), and their copolymers (PLGA), has generated a huge scientifi c and economic impact on a broad range of biomedical applications such as disposable medical devices, tissue engineering, drug delivery, and molecular targeting. [ 1, 2 ] However there have only been few innovations in new design of polylactone materials to meet the ever-growing need for functional biomaterials in medical applications, especially where new bioimaging techniques including optical imaging have become important enabling tools for innovation. [ 3 ] Herein, we report a series of newly developed biodegradable polylactone copolymers possessing photostable and in vivo detectable intrinsic fl uorescence without conjugating or encapsulating traditional photobleaching organic dyes or cytotoxic semiconducting quantum dots. We also demonstrate the applications of these new materials for in vivo real-time tracking of scaffold degradation and for theranostic cancer treatment.
Despite the exciting progress, some fundamental understandings on the key elements of tissue engineering are still lacking. For example, although it has been recognized that the scaffold degradation rate should match the rate of new tissue formation, biomaterial designs to control the in vivo scaffold degradation rate remain empirical due to the lack of quantitative in vivo validation. Currently, in vivo scaffold degradation is often estimated based on the outcomes of in vitro degradation measurements. [ 4, 5 ] Unfortunately, various factors have been tunable fl uorescence emission with varied amino acids (up to 725 nm), and superior photostability compared to organic dyes. [13] [14] [15] Herein, for the fi rst time, we report the synthesis and characterization of thermoplastic BPLPLs, exemplifi ed by BPLP-co -Poly(L-lactide) (BPLP-PLLA). The hydroxyl or carboxyl groups of BPLPs initiate ring-opening polymerization of lactone monomers such as lactide, glycolide, and caprolacone to make completely degradable block copolymers (BPLPLs) ( Figure 1 a) . The resulting BPLPL copolymers retained the intrinsic photoluminescence inherited from BPLPs, which enabled the feasibility of non-invasive imaging for monitoring the BPLPL scaffold degradation and tracking of cancer targeting BPLPL nanoparticles in vivo (Figure 1 b and 1 c) .
The synthesis route of BPLP-PLLA copolymer is illustrated in Figure 1 a. The BPLP:lactide molar ratios were varied as 1:20, 1:50, and 1:100. For example, BPLP-Cys-PLLA20 represents a copolymer that was synthesized from BPLP with L-cysteine as the amino acid component and the feeding molar ratio of BPLP-Cys to L-lactide of 1:20. As presented in our previous work, [ 13 ] water-soluble BPLPs (WBPLPs) were made with hydrophilic polyethylene glycol (PEG) chosen as the diol. Therefore, amphiphilic biodegradable photoluminescent WBPLP-PLLAs were also synthesized with WBPLP as the hydrophilic block and PLLA as the hydrophobic block. All polymers synthesized are summarized in Supplementary Table S1 . 1 H NMR and FTIR confi rm that the chemical structures of BPLP-PLLAs ( Figure S1 and S2, Supporting Information) consist of functional groups from both BPLPs and PLLA.
All BPLP-PLLA copolymers emitted strong fl uorescence, as shown in Figure 2 a and 2 b. For BPLP-Cys-PLLA, the maximum emission (441 nm) and excitation (377 nm) had slightly different from that of BPLP-Cys pre-polymer, which had maximum emission and excitation wavelengths of 434 and 365 nm, respectively. [ 13, 14 ] At the same concentration (10 mg/mL), the longer PLLA blocks were, the relatively weaker fl uorescent intensity was observed. BPLP-Ser-PLLA also emits tunable fl uorescent light depending on the excitation wavelength as similar to BPLP-Ser. [ 13, 14 ] As shown in Figure 2 b, BPLP-Ser-PLLA50 displayed fl uorescence emissions from 350 nm to 700 nm. In addition, BPLP-Cys-PLLA copolymers provided exceptionally high quantum yields (up to 51.4%, Table S1 , Supporting Information), which are in the range of traditional fl uorescent materials, including organic dyes, quantum dots, and green fl uorescent proteins. [ 15 ] One exceptional advantage of the BPLPs is the excellent photostability over traditional organic dyes. BPLPPLLAs inherit this property, which is a key feature for many bioimaging applications, [ 16 ] from BPLPs by showing much better photo-bleaching resistance against continuous illumination over photobleaching organic dyes, e.g. Rhodamine B and Fluorescein. (Figure 2 c) . The BPLP-PLLA polymers all possessed outstanding photostability with >90% signal remaining even after a long (3 hours) illumination. These intriguing fl uorescence properties will empower our novel degradable BPLPLs for both in vitro and in vivo detections.
The thermal properties of BPLP-PLLAs were characterized by Differential Scanning Calorimetry (DSC) and Thermal 
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Gravimetric Analysis (TGA). Figure S3a (Supporting Information) presents the DSC thermograms of BPLP-Cys-PLLA copolymers with various PLLA chain lengths. The glass transition temperature (Tg) increases gradually with the increasing of PLLA block lengths: 0, 12.2, and 40.1 °C for BPLP-Cys-PLLA20, BPLP-Cys-PLLA50, and BPLP-Cys-PLLA100, respectively. The same trend could also apply to BPLP-Ser-PLLA and WBPLP-PLLA ( Figure S4 , Supporting Information). Figure S3b (Supporting Information) also shows a representative DSC thermogram of BPLP-Cys-PLLA100 with a clear crystallization peak at 106.1 °C and a melting peak at 115.3 °C, which is lower than the typical melting point of PLLA (around 170 °C), [ 17 ] probably due to the incorporation of softer BPLP chains. Figure S5 (Supporting Information) characterizes the thermal decomposition temperatures of BPLP-Cys-PLLA copolymers. BPLP-Cys-PLLA20 exhibited a slight weight loss at 120 °C, possibly due to the loss of water from carboxyl group. However, no weight loss was observed before 280 °C for BPLP-Cys-PLLA100, in common with commercial PLLA. [ 17 ] Unlike BPLPs, all BPLPLs could not be thermally crosslinked upon heating, suggesting they are thermoplastic materials. With similar thermal properties to PLLA, our BPLP-PLLAs can be processed into various forms, including fi lms, scaffolds, particles, micelles and fi bers for a broad range of biomedical applications. BPLP-Ser-PLLA particle sizes and drug delivery profi les can also be easily tuned by varying the molecular design of polymers ( Figure S6 , Supporting Information). Previously mentioned amphiphilic WBPLP-PLLAs were also prepared into micelles with controllable critical micelle concentration ( Figure S7 , Supporting Information). Both nanoparticles and micelles exhibited strong fl uorescence in aqueous solutions ( Figure S8 , Supporting Information). Importantly, BPLP-Ser-PLLA50 nanoparticles that were taken up by 3T3 fi broblasts in vitro could be imaged by fl uorescent microscopy, verifying the cell labeling capability of BPLPLs that is similar to fl uorescent dyes and quantum dots (Figure 2 d) . BPLP-PLLA nanoparticles were also tested as drug delivery carriers using 5-fl uorouracil as a model drug and the release profi le was tailored simply by varying the molecular weight of PLLA chain ( Figure S9 , Supporting Information). In addition, BPLP-Ser-PLLA50 polymers were electrospun into uniform ultra-fi ne fi bers that exhibited strong photoluminescence ( Figure S10 , Supporting Information). Electrospun fi bers have been widely used in tissue engineering as the nano-fi brous structures mimic the structures of extracellular matrix such as collagen and elastin. Thus, BPLPLs demonstrate excellent processability, which is exemplifi ed by the fabrication of fi lms, particles, fi bers and scaffolds suggesting that BPLPLs may serve as candidate materials for a number of biomedical applications such as tissue engineering, drug delivery, and bioimaging.
To assess the cytotoxicity of BPLPLs, BPLP-Cys-PLLA nanoparticles were cultured with mouse 3T3 fi broblasts. As shown in Figure S11 (Supporting Information) BPLP-Cys-PLLA nanoparticles exhibit lower cytotoxicity than the pristine BPLP-Cys nanoparticles at high concentrations and similar toxicity in vitro to the widely used PLLA nanoparticles. To assess the in vivo host response of BPLP-PLLA, BPLP-Ser-PLLA20 fi lms were implanted subcutaneously in 1-year-old male Sprague Dawley rats. PLLA (Mw = 20 kDa) fi lms and crosslinked BPLP-Ser fi lms were chosen as controls. Histological analysis showed the presence of infl ammatory cells at both 1 and 10 weeks of implantation ( Figure S12 , Supporting Information). After 1 week of implantation, the acute infl ammatory response was mild for all samples. There was no signifi cant difference ( p > 0.05) observed among PLLA, CBPLP fi lms and BPLP-Ser-PLLA20 in terms of cell density surrounding the implants, while the cell numbers for all samples decreased signifi cantly ( p 0.01) at week 10 ( Figure S12b) . Noticeably, the fi brotic capsule thicknesses for CBPLP and BPLP-Ser-PLLA20 was signifi cantly thinner than that for PLLA ( p 0.01) at both week 1 and week 10 ( Figure S12c) , likely due to the soft, elastic and hydrophilic nature of CBPLP and BPLP-Ser-PLLA20 compared to PLLA. The fi brotic capsule layer thickness for each sample also decreased and stabilized at week 10. One week after the implantation, CD11b+ infl ammatory cell were identifi ed around the implanted materials (Figure S12a ). This immunohistochemical analysis ( Figure S12d ) revealed almost the same number of CD11b+ infl ammatory cells around CBPLP and BPLP-Ser-PLLA20 implants as around PLLA ( p 0.05). The above animal studies indicated that BPLP-PLLAs generated comparable or even better in vivo tissue responses as compared to the commercial PLLA.
Degradation is a critical property of biomaterials, since it affects cytotoxicity, cell penetration/proliferation, drug release rate, mechanical performance, and many other properties. [ 18 ] As expected, the in vitro weight loss of BPLP-PLLAs mainly depended on the length of hydrophobic PLLA blocks ( Figure 3 a) . BPLP-Cys-PLLA20 completely degraded after 12 weeks of incubation in PBS, while the degradation rate of BPLP-Cys-PLLA100 was similar to that of PLLA homopolymer with a similar molecular weight. [ 19 ] One of the most signifi cant advantages of BPLP-PLLAs is that their degradation can be measured by fl uorescent signal decay in addition to the traditional weight loss measurements. We fi rst confi rmed that the normalized fl uorescence signal loss matched the weight loss of BPLP-PLLAs in vitro (correlation coeffi cient of two covariance = 0.997) (Figure 3 b) . This phenomenon supports our hypothesis that fl uorescence decay can be used as a measurement of material degradation. Thus, we can monitor the in vivo degradation of BPLP-PLLAs non-invasively by tracking the fl uorescence decay of polymers under an in vivo fl uorescent imaging system without extracting the implants or sacrifi cing animals (Figure 3 d) . As shown in Figure 3 c, the weight of BPLP-Ser-PLLA20 decreased much faster in PBS in vitro than in the living body at all time points, especially for the fi rst 5 weeks (correlation coeffi cient = 0.946), likely due to the relatively large volume of liquid in in vitro degradation compared to the relatively small volume of subcutaneous fl uid in animals. Interestingly, by comparing in vivo fl uorescence decay and in vivo material degradation, we found that the rate of fl uorescence loss was slightly higher than the rate of actual weight loss in fi rst two weeks, and observed a signifi cantly higher fl uorescence signal loss at week 3. Although the cause has yet to be determined, it is possible that the acute infl ammatory cells and protein-rich interstitial fl uids block some fl uorescence. [ 20 ] Nonetheless, the fl uorescence decay still showed a better correlation to the in vivo weight loss compared to in vitro weight loss. When acute infl ammation (loose connective tissues) is transformed into mild chronic infl ammation (thin fi brotic capsules) after 4 weeks, it is expected that fl uorescence decay should better represent the actual material degradation. [ 5, 21 ] Indeed, we observe that the fl uorescence decay after 4 weeks matched (correlation coeffi cient = 0.987) the in vivo weight loss of the BPLP-Ser-PLLA20 samples. Histological images also confi rm that after 10 weeks in vivo implantation, BPLP-Ser-PLLA20 fi lms degraded into small pieces and the infi ltrated tissues occupied the spaces of the degraded materials ( Figure S13 in vivo. It is noteworthy that BPLPs and PLA are all aliphatic polyesters, thus the degradation mechanism of both is the hydrolysis of ester bonds. During a bulk degradation process, the ester bonds cleaved randomly, resulting in that fl uorescence loss rate matches the whole polymer degradation rate. Conferring in vivo detectable fl uorescent properties to biodegradable polymers may advance the fi eld of tissue engineering as the enabling imaging tool may facilitate obtaining the true understanding on material degradation and tissue material interactions in situ and in real time.
With the unique intrinsic fl uorescence, BPLP-PLLAs can be used as a label-free in vivo imaging tool for cancer detection and treatment. To demonstrate the feasibility, targeting ligand folates were conjugated on BPLP-Ser-PLLA50 nanoparticles, [ 22 ] which were stable in physiological conditions ( Figure S14 , Supporting Information). After i.v. injection through the tail vein, these nanoparticles quickly accumulated at the dorsal orthotopic breast tumors (MCF7 cell injected subcutaneously) of a nude mouse within 4-6 hours as detected by in vivo fl uorescent imaging system (Figure 2 e) . Ex vivo fl uorescent imaging ( Figure S15 , Supporting Information) confi rms that substantial higher fl uorescent intensities were found in tumor tissue than in liver. These results support that BPLP-PLLAs nanoparticle preferentially accumulated at tumor sites. Since drugs can also be easily encapsulated with BPLP-PLLA nanoparticles as well (Figure S9 ), the feasibility of applying BPLPLs into theranostic cancer management is obvious. Furthermore, the high targeting effi ciency is probably a result of high density of targeting folates on the nanoparticle surfaces, since folates do not need to share conjugation sites with imaging molecules as in most existing nanoparticle systems. [ 23 ] Thus, our BPLP-PLLA nanoparticles can potentially serve as ideal candidates for in vivo cancer fl uorescence imaging and drug delivery, without the need of conjugation with any organic dyes or quantum dots.
In conclusion, we have successfully synthesized and characterized biodegradable photoluminescent polylactone (BPLPL), representatively BPLP-PLLA copolymers. These fully degradable polymers exhibited similar thermal properties and biocompatibility to the commercial polylactones. Most importantly, BPLPLs enabled non-invasive fl uorescence imaging for tracking in vivo degradation of polymers. BPLPLs can be fabricated into different forms such as nanoparticles for potential theranostic applications. We demonstrated that incorporating BPLP units into biodegradable polymer design can be an effective way to integrate intrinsically photoluminescent properties into biodegradable polymers. Given the already signifi cant impact generated by using polylactone materials, conferring intriguing in vivo detectable photobleaching-resistant photoluminescence to polylactone represents an innovation that should advance the understanding, design, and use of biodegradable polymers in a broad range of biomedical and biological applications where fl uorescence imaging and sensing have gained increasing importance.
Experimental Section
Experimental details are described in the Supporting Information.
Supporting Information
Supporting Information is available online from the Wiley Online Library or from the author. A detailed experimental section is provided.
Experimental Section

Synthesis of BPLPs and BPLP-polylactone copolymers (BPLPLs): BPLP prepolymers with
terminal hydroxyl groups were synthesized by reacting citric acid with diol in a molar ratio of 1:1.1 as described previously. [1] L-Cysteine and L-serine were selected to synthesize BPLPCys and BPLP-Ser. Polyethylene glycol (MW=200 Da) was also used as a diol to prepare water-soluble BPLP (WBPLP). BPLPLs were synthesized via enzyme catalyzed ring-opening polymerization using pre-BPLP as macro-initiators. Typically, freeze-dried pre-BPLP was added into a dry 100 mL flask, and then lactones (for example, L-lactide) (purchased from Sigma-Aldrich, recrystallized twice in ethyl acetate before polymerization) were added into the flask with different ratios to BPLP. Next, porcine pancreas lipase (PPL, dried overnight under vacuum) was added into the flask with a ratio of 5% to lactone. The flask was vacuumed and purged with nitrogen three times, then sealed and heated to 100°C for 72 hrs.
The copolymer was dissolved in chloroform and PPL was removed by filtration through a fritted filter. The polymer solution was concentrated under reduced pressure and then precipitated in cold ethanol. In case of using water-soluble pre-BPLP to synthesize amphiphilic copolymer, the product was dissolved by dimethyl sulfoxide (DMSO) and precipitate in cold DI water after filtration. Similar reactions were also conducted in 1, 4-dioxane at 100°C to synthesize BPLPLs in solutions. For the following in vitro and in vivo tests, polymers prepared by melt polymerization were used.
Preparation of films, nanoparticles, micelles and nanofibers:
BPLP-PLLA films were prepared by casting their chloroform solution into Teflon molds and followed by evaporation.
The BPLP-PLLA nanoparticles were prepared using the nanoprecipitation technique. 5 mg of the BPLP-PLLA polymer was dissolved in 5 mL of THF. The polymeric solution was added dropwise to 50 mL of deionized water. The solution was stirred at a speed of 700 rpm and the solvent was completely evaporated at room temperature. WBPLP-PLLA micelles were fabricated through a similar method. Fluorescent nanofibers were fabricated by electrospinning 12% BPLP-Ser-PLLA50 chloroform solution at 18kV and 2.5 µL/min onto an aluminum board.
Polymer Characterization: Fourier Transform Infrared Spectra (FTIR) was collected at room temperature. The copolymer dissolved in chloroform was cast over a KBr pellet. The solvent was allowed to evaporate overnight in a chemical hood. FTIR spectra were collected using a Nicolet 6700 FTIR spectrometer (Thermo Fisher Scientific) at room temperature. For 1 H NMR measurements, 10 mg of copolymer was dissolved in 1 mL of deuterated chloroform or DMSO. The NMR spectra were collected on a JEOL 500 MHz spectrometer at room temperature.
Photoluminescent properties: UV-vis absorption spectra were collected using a Shimadzu UV-2450 spectrophotometer. A dilute solution of copolymer was prepared in DMSO. All photoluminescence spectra were obtained by Shimadzu RF-5301PC fluorospectrophotometer.
Both the excitation and the emission slit width were set at 1.5 nm for all samples unless otherwise stated. Quantum yield of all samples was determined by Williams' method. [2] Anthracene (quantum yield = 27% in ethanol) was used as the standard. Photo-stability measurement was conducted by continuously illuminating the polymer solutions with excitation light at 365nm and emission at 430nm for 3 hours. Rhodamine B and Fluorescein aqueous solutions were tested for their photostability at their maximum excitation and emission wavelength for the same period of time.
Thermal properties: Thermal analysis was conducted on a differential scanning calorimeter (DSC, TA Instrument Q2000) at a heating ramp rate of 10˚C/min. A thermogravimetric analyzer (TGA, TA instrument Q500) was used to measure the thermal degradation of the polymers at a ramp rate of 10˚C/min from 0˚C to 500˚C.
In vitro degradation:
The in vitro degradation of the polymers was done with 50 mg of copolymer placed in a tube containing 10ml of phosphate buffer saline (PBS) (pH=7.4). All samples were incubated at 37°C for predetermined times. At each time point, the samples were taken out, washed with water and lyophilized. The degradation was characterized by mass remaining. The in vitro degradation was also monitored by fluorescence loss. Cell uptake and fluorescence labeling: The cell uptake of the fluorescent nanoparticles was also examined in vitro. 3T3 fibroblasts were seeded onto sterile cover slips at a density of 5,000 cells/mL. Cells were allowed to attach and grow for 24 hours before uptake studies were performed. The cover slips were washed with PBS and transferred into a Petri dish.
Cell culture and in vitro studies
After 4 hours incubation with BPLP-Ser-PLLA50 nanoparticles (100 µg/mL), the medium was aspirated and the cells were washed three times with PBS to remove the excess nanoparticles, which had not been taken up. The cells were fixed with 2.5% glutaraldehyde for 2 hours. After fixing, the cover slips were mounted on glass slides and imaged under a Leica DMLP fluorescence microscope (Leica Microsystems, Bannockbum, IL) equipped with a Nikon E500 Camera (8.4V, 0.9A, Nikon Corp., Japan). (1 and 10 weeks), four animals were sacrificed with excess CO2, and polymers with surrounding tissues were harvested for further evaluation. The explants were fixed by soaking in 10% formalin for 2 days, then embedded in paraffin wax, and sectioned into 4 µm sections.
Six slides from different areas of the explants were stained with hematoxylin & eosin (H&E) and CD11b immunohistochemistry. The cross-sections were examined using a Leica DMLP microscope (Leica Microsystems Inc., Bannockburn, IL) fitted with a Nikon E500 camera (Nikon Corp., Japan).
Tumor targeted imaging: An MCF7 human breast tumor xenograft (1x10 5 MCF7 cells were injected on the back of a 6 week nude mouse) was used for in vivo tumor targeting and imaging. BPLP-Ser-PLLA50 nanoparticles were conjugated with folate by EDC/NHS chemistry before injected intravenous injection in the tail vein into mice at a concentration of 5 mg/mL and volume of 200 µL. After 4 and 6 hours, the animals were imaged using a Maestro TM in vivo fluorescent imaging system, as described above. The animals were also sacrificed 8 hours post-injection and some organs including heart, liver, lung, spleen, kidney and tumor tissues were taken out to study the nanoparticle biodistribution via fluorescent imaging. Table S1 . Molecular and fluorescent characterization of different BPLP-PLLA copolymers. 
